Taking Affiliate Quality into the future

How quality organisations must evolve to be future-ready

Biopharmaceuticals face challenges arising from a number of converging trends. It is essential that the function responsible for ensuring that high quality biopharmaceutical medicines reach healthcare professionals, hospitals, and patients in markets, as and when needed – Affiliate Quality (AQ) – is able to keep pace with demands and become a partner to the business.

Our latest white paper explores the role and development of AQ in today’s dynamic industry. By benchmarking ten of the world’s leading biopharmaceuticals, we’ve been able to understand the best practices that are enabling some to generate greater value from AQ, as well as pinpoint the strategic choices that must be made to develop an AQ function that’s fit for purpose in a fast-changing industry.

Download the report

Our key findings summarised

Challenge #1

As health markets and the pharmaceutical landscape continue to evolve, AQ is facing a more complex and demanding work environment. Not surprisingly, “AQ resources are constrained/limited” is ranked as the most pressing challenge for AQ. And, all participating biopharmaceuticals recognize both the need to evolve their AQ operations, and the benefits from doing so.

Future quality

67% of all benchmark survey participants perceive AQ as a competitive advantage for their company, confirming AQ’s instrumental role in ensuring that high quality biopharmaceutical medicines reach healthcare professionals, hospitals, and patients in markets, as and when needed.

Developing talent in AQ

Our research and working with AQ organisations shows that best in class biopharmaceuticals have invested greater time and effort in the past to enhance the effectiveness of their AQ and grow the value it generates. E.g. they are strongly focusing on making the AQ job more attractive and increasing business partnering capabilities of AQ resources to help them play a more strategic role.